Cell Genesys, Inc. (NASDAQ: CEGE) has their focus on developing and commercializing novel biological therapies for cancer patients. GVAX® cancer imunotherapy, the company’s lead product platform, holds the potential to treat several types of cancer. Cell Genesys also holds an equity interest in its former subsidiary, Ceregene, Inc., which is developing gene therapies for neurodegenerative disorders. For further information, visit the Company’s web site at www.cellgenesys.com.
- 18 years ago
QualityStocks
Cell Genesys, Inc. (NASDAQ: CEGE)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Moves GelrinC Closer to Regulatory and Commercial Milestones
Regentis Biomaterials (NYSE American: RGNT) is advancing its GelrinC hydrogel-based cartilage regeneration technology toward key clinical, regulatory…
-
Wrap Technologies Inc. (NASDAQ: WRAP) Positions Non-Lethal Innovation at the Center of Public Safety Reform
WRAP offerings illustrate a broader industry trend toward building connected ecosystems rather than standalone products.…
-
Brownfield Gold Projects Could Hold an Edge in Today’s Permitting Environment
Disseminated on behalf of Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) and may include paid advertising.…